N | % | Median (IQR) | |
Patients | 333 | ||
Death | 114 | ||
Age, years | 71 (62–77) | ||
<65 | 104 | 31.2 | |
65–74 | 109 | 32.7 | |
≥75 | 120 | 36.0 | |
Female | 210 | 63.1 | |
RA and PMR | 52 | 15.6 | |
Psoriatic arthritis and spondylarthritis | 0 | 0.0 | |
Primary vasculitis syndrome | 116 | 34.8 | |
Systemic lupus erythematosus | 49 | 14.7 | |
Inflammatory myositis | 60 | 18.0 | |
Systemic sclerosis | 13 | 3.9 | |
Others | 43 | 12.9 | |
Concomitant ILD | 122 | 36.6 | |
Admission to an advanced treatment hospital | 94 | 28.2 | |
Bronchoscopy | 36 | 10.8 | |
Intensive care management | 37 | 11.1 | |
Ventilator use | 83 | 24.9 | |
Length of hospital stay after starting PCP treatment, days | 33 (4–37) | ||
Glucocorticoid therapy | |||
Concomitant glucocorticoid use | 322 | 96.7 | |
Glucocorticoid pulse therapy | 103 | 30.9 | |
Antibiotics for PCP | |||
ST monotherapy | 214 | 64.3 | |
Others | 119 | 35.7 | |
PTM group | 80 | 24.0 | |
PTM monotherapy | 32 | 8.4 | |
ST → PTM | 48 | 14.4 | |
ATO group | 29 | 8.7 | |
ATO monotherapy | 9 | 2.7 | |
ST → ATO | 20 | 6.0 | |
Other combinations | 10 | 3.0 | |
Adjunctive therapy | |||
Gamma-globulin | 31 | 9.3 | |
Albumin | 40 | 12.0 | |
Empiric antibiotic therapy | 245 | 73.6 | |
Antifungal drugs | 110 | 33.0 | |
Anticytomegalovirus drugs | 56 | 16.8 |
ATO, atovaquone; ILD, interstitial lung disease; PCP, pneumocystis pneumonia; PMR, polymyalgia rheumatica; PTM, pentamidine; RA, rheumatoid arthritis; ST, sulfamethoxazole/trimethoprim.